Novo Nordisk Launches Rebinyn(R) in the United States for People with Hemophilia B

PLAINSBORO, N.J., Feb. 8, 2018 -- (Healthcare Sales & Marketing Network) -- Novo Nordisk, a global healthcare company, today announced that Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated, is now available in the United States for the tr... Biopharmaceuticals, Product Launch Novo Nordisk, Rebinyn, Coagulation Factor IX, Hemophilia B
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news